As of late, it has definitely been a great time to be an investor of Onconova Therapeutics, Inc. (ONTX).
Onconova (ONTX) will focus on the updates on lead candidate, Rigosertib, when it reports fourth-quarter 2019 results.
NEWTOWN, Pa., May 14, 2020 -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to.
There is a high frequency of RAS mutations in cancer that leads to the belief that mutations of the RAS Pathway provide a proliferative advantage and thus are involved in the pathogenesis of cancer. As a result, targeting the RAS pathway has been the objective of scientific research for decades.
NEWTOWN, Pa., March 24, 2020 -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to.
Q1 2020 Onconova Therapeutics Inc Earnings Call
As of late, it has definitely been a great time to be an investor in Onconova Therapeutics.
The Zacks Analyst Blog Highlights: Apple, Eagle Bancorp Montana, Onconova Therapeutics, Proteostasis Therapeutics and Abeona Therapeutics
Q4 2019 Onconova Therapeutics Inc Earnings Call
With the coronavirus threat increasing, it's quite evident that companies having significant exposure to China and the global economy are vulnerable. However, domestic producers of goods should remain unaffected.
Onconova Therapeutics, Inc. (ONTX), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced that Dr. Steven M. Fruchtman, President and Chief Executive Officer, will present a company update at the BIO CEO & Investor Conference February 10-11, 2020. Using a proprietary chemistry platform, Onconova has created a pipeline of targeted agents designed to work against specific cellular pathways that are important in cancer cells.
Onconova Therapeutics, Inc. (ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a focus on myelodysplastic syndromes (MDS), today announced that the Company will release its year-end 2019 financial results on Tuesday, March 24, 2020, after the market closes. Onconova has a pipeline of proprietary targeted agents designed to work against specific cellular pathways that are important in cancer cells.
The Bucks County firm's licensing deal with a Chinese drug company was voided after required payments were allegedly not made.
Drug developers are considered essential business, but the coronavirus has split staffs between home offices and labs.
The Zacks Analyst Blog Highlights: Onconova Therapeutics, Abeona Therapeutics, Proteostasis Therapeutics, Applied Therapeutics and Ennis
Onconova Therapeutics, Inc. (ONTX), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced that Dr. Steven M. Fruchtman, President and Chief Executive Officer, will present a company update at NobleCon16 - Noble Capital Markets’ Sixteenth Annual Investor Conference, February 17-18, 2020, being held in Hollywood, FL. A video webcast of the presentation will be available the following day on the Company’s website at https://investor.onconova.com/events-and-presentations, and as part of a complete catalog of presentations available on Noble Capital Markets’ Conference website: www.nobleconference.com and on Channelchek: www.channelchek.com, the investor portal created by Noble.
Onconova Therapeutics, Inc. (ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced the nomination of biotech industry veteran Terri Shoemaker to the Company’s Board of Directors. Ms. Shoemaker brings more than 30 years of extensive commercial and leadership experience to Onconova. Ms. Shoemaker will join as a Director on Onconova’s Board of Directors following election of the slate of directors at the annual general meeting of stockholders scheduled for May 27, 2020.
Onconova Therapeutics, Inc. (ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced that, as disclosed in the Company’s Definitive Proxy Statement for the Company’s 2020 Annual Meeting of Stockholders, due to the public health impact of the COVID-19 pandemic, the Company’s Annual Meeting of Stockholders will be held in a virtual meeting webcast format, beginning at 10:30 a.m. EDT on Wednesday, May 27, 2020. Stockholders will not be able to attend the Annual Meeting in person. Onconova stockholders as of the close of business on March 30, 2020 can join the live virtual meeting.
Onconova Therapeutics, Inc. (ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced that the Company will release its first quarter financial results on Thursday, May 14, 2020, after the market closes. To facilitate an on-time conference call start, Onconova recommends that participants dial in 15 minutes before the 4:30 p.m. ET start time. Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel drugs to treat cancer, with an initial focus on myelodysplastic syndromes (MDS).
The US dollar drew support from a healthy domestic economy, and Fed's cautiously optimistic stance about holding interest rates despite the coronavirus outbreak.